Quality assurance for Duchenne and Becker muscular dystrophy genetic testing: Development of a genomic DNA reference material panel

Lisa Kalman, Jay Leonard, Norman Gerry, Jack Tarleton, Christina Bridges, Julie M. Gastier-Foster, Robert E. Pyatt, Eileen Stonerock, Monique A. Johnson, Carolyn (Sue) Richards, Iris Schrijver, Tianhui Ma, Vanessa Rangel Miller, Yetsa Adadevoh, Pat Furlong, Christine Beiswanger, Lorraine Toji

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Duchenne and Becker muscular dystrophies (DMD/BMD) are allelic X-linked recessive disorders that affect approximately 1 in 3500 and 1 in 20,000 male individuals, respectively. Approximately 65% of patients with DMD have deletions, 7% to 10% have duplications, and 25% to 30% have point mutations in one or more of the 79 exons of the dystrophin gene. Most clinical genetics laboratories test for deletions, and some use technologies that can detect smaller mutations and duplications. Reference and quality control materials for DMD/BMD diagnostic and carrier genetic testing are not commercially available. To help address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the genetic testing and the DMD/BMD patient communities and the Coriell Cell Repositories, have characterized new and existing cell lines to create a comprehensive DMD/BMD reference material panel. Samples from 31 Coriell DMD cell lines from male probands and female carriers were analyzed using the Affymetrix SNP Array 6.0 and Multiplex Ligation-Dependent Probe Amplification (MRC-Holland BV, Amsterdam, the Netherlands), a multiplex PCR assay, and DNA sequence analysis. Identified were 16 cell lines with deletions, 9 with duplications, and 4 with point mutations distributed throughout the dystrophin gene. There were no discordant results within assay limitations. These samples are publicly available from Coriell Institute for Medical Research (Camden, NJ) and can be used for quality assurance, proficiency testing, test development, and research, and should help improve the accuracy of DMD testing.

Original languageEnglish (US)
Pages (from-to)167-174
Number of pages8
JournalJournal of Molecular Diagnostics
Volume13
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Duchenne Muscular Dystrophy
Genetic Testing
Dystrophin
Multiplex Polymerase Chain Reaction
Point Mutation
Cell Line
Netherlands
DNA
Centers for Disease Control and Prevention (U.S.)
DNA Sequence Analysis
Quality Control
Genes
Single Nucleotide Polymorphism
Biomedical Research
Exons
Technology
Mutation
Research

ASJC Scopus subject areas

  • Molecular Medicine
  • Pathology and Forensic Medicine

Cite this

Quality assurance for Duchenne and Becker muscular dystrophy genetic testing : Development of a genomic DNA reference material panel. / Kalman, Lisa; Leonard, Jay; Gerry, Norman; Tarleton, Jack; Bridges, Christina; Gastier-Foster, Julie M.; Pyatt, Robert E.; Stonerock, Eileen; Johnson, Monique A.; Richards, Carolyn (Sue); Schrijver, Iris; Ma, Tianhui; Miller, Vanessa Rangel; Adadevoh, Yetsa; Furlong, Pat; Beiswanger, Christine; Toji, Lorraine.

In: Journal of Molecular Diagnostics, Vol. 13, No. 2, 03.2011, p. 167-174.

Research output: Contribution to journalArticle

Kalman, L, Leonard, J, Gerry, N, Tarleton, J, Bridges, C, Gastier-Foster, JM, Pyatt, RE, Stonerock, E, Johnson, MA, Richards, CS, Schrijver, I, Ma, T, Miller, VR, Adadevoh, Y, Furlong, P, Beiswanger, C & Toji, L 2011, 'Quality assurance for Duchenne and Becker muscular dystrophy genetic testing: Development of a genomic DNA reference material panel', Journal of Molecular Diagnostics, vol. 13, no. 2, pp. 167-174. https://doi.org/10.1016/j.jmoldx.2010.11.018
Kalman, Lisa ; Leonard, Jay ; Gerry, Norman ; Tarleton, Jack ; Bridges, Christina ; Gastier-Foster, Julie M. ; Pyatt, Robert E. ; Stonerock, Eileen ; Johnson, Monique A. ; Richards, Carolyn (Sue) ; Schrijver, Iris ; Ma, Tianhui ; Miller, Vanessa Rangel ; Adadevoh, Yetsa ; Furlong, Pat ; Beiswanger, Christine ; Toji, Lorraine. / Quality assurance for Duchenne and Becker muscular dystrophy genetic testing : Development of a genomic DNA reference material panel. In: Journal of Molecular Diagnostics. 2011 ; Vol. 13, No. 2. pp. 167-174.
@article{833bb1034edd41a79512e9039aa3cb20,
title = "Quality assurance for Duchenne and Becker muscular dystrophy genetic testing: Development of a genomic DNA reference material panel",
abstract = "Duchenne and Becker muscular dystrophies (DMD/BMD) are allelic X-linked recessive disorders that affect approximately 1 in 3500 and 1 in 20,000 male individuals, respectively. Approximately 65{\%} of patients with DMD have deletions, 7{\%} to 10{\%} have duplications, and 25{\%} to 30{\%} have point mutations in one or more of the 79 exons of the dystrophin gene. Most clinical genetics laboratories test for deletions, and some use technologies that can detect smaller mutations and duplications. Reference and quality control materials for DMD/BMD diagnostic and carrier genetic testing are not commercially available. To help address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the genetic testing and the DMD/BMD patient communities and the Coriell Cell Repositories, have characterized new and existing cell lines to create a comprehensive DMD/BMD reference material panel. Samples from 31 Coriell DMD cell lines from male probands and female carriers were analyzed using the Affymetrix SNP Array 6.0 and Multiplex Ligation-Dependent Probe Amplification (MRC-Holland BV, Amsterdam, the Netherlands), a multiplex PCR assay, and DNA sequence analysis. Identified were 16 cell lines with deletions, 9 with duplications, and 4 with point mutations distributed throughout the dystrophin gene. There were no discordant results within assay limitations. These samples are publicly available from Coriell Institute for Medical Research (Camden, NJ) and can be used for quality assurance, proficiency testing, test development, and research, and should help improve the accuracy of DMD testing.",
author = "Lisa Kalman and Jay Leonard and Norman Gerry and Jack Tarleton and Christina Bridges and Gastier-Foster, {Julie M.} and Pyatt, {Robert E.} and Eileen Stonerock and Johnson, {Monique A.} and Richards, {Carolyn (Sue)} and Iris Schrijver and Tianhui Ma and Miller, {Vanessa Rangel} and Yetsa Adadevoh and Pat Furlong and Christine Beiswanger and Lorraine Toji",
year = "2011",
month = "3",
doi = "10.1016/j.jmoldx.2010.11.018",
language = "English (US)",
volume = "13",
pages = "167--174",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "2",

}

TY - JOUR

T1 - Quality assurance for Duchenne and Becker muscular dystrophy genetic testing

T2 - Development of a genomic DNA reference material panel

AU - Kalman, Lisa

AU - Leonard, Jay

AU - Gerry, Norman

AU - Tarleton, Jack

AU - Bridges, Christina

AU - Gastier-Foster, Julie M.

AU - Pyatt, Robert E.

AU - Stonerock, Eileen

AU - Johnson, Monique A.

AU - Richards, Carolyn (Sue)

AU - Schrijver, Iris

AU - Ma, Tianhui

AU - Miller, Vanessa Rangel

AU - Adadevoh, Yetsa

AU - Furlong, Pat

AU - Beiswanger, Christine

AU - Toji, Lorraine

PY - 2011/3

Y1 - 2011/3

N2 - Duchenne and Becker muscular dystrophies (DMD/BMD) are allelic X-linked recessive disorders that affect approximately 1 in 3500 and 1 in 20,000 male individuals, respectively. Approximately 65% of patients with DMD have deletions, 7% to 10% have duplications, and 25% to 30% have point mutations in one or more of the 79 exons of the dystrophin gene. Most clinical genetics laboratories test for deletions, and some use technologies that can detect smaller mutations and duplications. Reference and quality control materials for DMD/BMD diagnostic and carrier genetic testing are not commercially available. To help address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the genetic testing and the DMD/BMD patient communities and the Coriell Cell Repositories, have characterized new and existing cell lines to create a comprehensive DMD/BMD reference material panel. Samples from 31 Coriell DMD cell lines from male probands and female carriers were analyzed using the Affymetrix SNP Array 6.0 and Multiplex Ligation-Dependent Probe Amplification (MRC-Holland BV, Amsterdam, the Netherlands), a multiplex PCR assay, and DNA sequence analysis. Identified were 16 cell lines with deletions, 9 with duplications, and 4 with point mutations distributed throughout the dystrophin gene. There were no discordant results within assay limitations. These samples are publicly available from Coriell Institute for Medical Research (Camden, NJ) and can be used for quality assurance, proficiency testing, test development, and research, and should help improve the accuracy of DMD testing.

AB - Duchenne and Becker muscular dystrophies (DMD/BMD) are allelic X-linked recessive disorders that affect approximately 1 in 3500 and 1 in 20,000 male individuals, respectively. Approximately 65% of patients with DMD have deletions, 7% to 10% have duplications, and 25% to 30% have point mutations in one or more of the 79 exons of the dystrophin gene. Most clinical genetics laboratories test for deletions, and some use technologies that can detect smaller mutations and duplications. Reference and quality control materials for DMD/BMD diagnostic and carrier genetic testing are not commercially available. To help address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the genetic testing and the DMD/BMD patient communities and the Coriell Cell Repositories, have characterized new and existing cell lines to create a comprehensive DMD/BMD reference material panel. Samples from 31 Coriell DMD cell lines from male probands and female carriers were analyzed using the Affymetrix SNP Array 6.0 and Multiplex Ligation-Dependent Probe Amplification (MRC-Holland BV, Amsterdam, the Netherlands), a multiplex PCR assay, and DNA sequence analysis. Identified were 16 cell lines with deletions, 9 with duplications, and 4 with point mutations distributed throughout the dystrophin gene. There were no discordant results within assay limitations. These samples are publicly available from Coriell Institute for Medical Research (Camden, NJ) and can be used for quality assurance, proficiency testing, test development, and research, and should help improve the accuracy of DMD testing.

UR - http://www.scopus.com/inward/record.url?scp=79952262577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952262577&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2010.11.018

DO - 10.1016/j.jmoldx.2010.11.018

M3 - Article

C2 - 21354051

AN - SCOPUS:79952262577

VL - 13

SP - 167

EP - 174

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 2

ER -